Key Details
Annual Revenue
$27.34 MAnnual ROE
-56.92%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
N/ARecent annual earnings:
N/ANext ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
04 May '21 SVB Leerink
Outperform04 May '21 Credit Suisse
Outperform04 May '21 B of A Securities
BuyScreeners with VECT included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
VectivBio Holding AG doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
Why Shares of VectivBio Holding Are Up Today
VECT
The Motley Fool22 May 2023
Ironwood Pharmaceuticals' buyout deal is worth $1 billion. The attraction was VectivBio's late-stage therapy, apraglutide.
FAQ
- What is the primary business of VectivBio Holding AG?
- What is the ticker symbol for VectivBio Holding AG?
- Does VectivBio Holding AG pay dividends?
- What sector is VectivBio Holding AG in?
- What industry is VectivBio Holding AG in?
- What country is VectivBio Holding AG based in?
- When did VectivBio Holding AG go public?
- Is VectivBio Holding AG in the S&P 500?
- Is VectivBio Holding AG in the NASDAQ 100?
- Is VectivBio Holding AG in the Dow Jones?
- When does VectivBio Holding AG report earnings?
- Should I buy VectivBio Holding AG stock now?
What is the primary business of VectivBio Holding AG?
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.
What is the ticker symbol for VectivBio Holding AG?
The ticker symbol for VectivBio Holding AG is NASDAQ:VECT
Does VectivBio Holding AG pay dividends?
No, VectivBio Holding AG does not pay dividends
What sector is VectivBio Holding AG in?
VectivBio Holding AG is in the Healthcare sector
What industry is VectivBio Holding AG in?
VectivBio Holding AG is in the Biotechnology industry
What country is VectivBio Holding AG based in?
VectivBio Holding AG is headquartered in Switzerland
When did VectivBio Holding AG go public?
VectivBio Holding AG's initial public offering (IPO) was on 08 April 2021
Is VectivBio Holding AG in the S&P 500?
No, VectivBio Holding AG is not included in the S&P 500 index
Is VectivBio Holding AG in the NASDAQ 100?
No, VectivBio Holding AG is not included in the NASDAQ 100 index
Is VectivBio Holding AG in the Dow Jones?
No, VectivBio Holding AG is not included in the Dow Jones index
When does VectivBio Holding AG report earnings?
The date for VectivBio Holding AG's next earnings report has not been announced yet
Should I buy VectivBio Holding AG stock now?
As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions